Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.57 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116825 | 1.00 | AAK1 (0.57) | AAK1SCN10ATRPV1MLKLLCK | |
| SCHEMBL20054545 | 0.93 | AAK1 (0.64) | AAK1SCN10ATRPV1MLKLLCK | |
| SCHEMBL15116826 | 0.93 | AAK1 (0.64) | AAK1SCN10ATRPV1MLKLLCK | |
| SCHEMBL20054558 | 0.84 | AAK1 (0.55) | AAK1SCN10ATRPV1MLKLLCK | |
| SCHEMBL15116865 | 0.84 | AAK1 (0.55) | AAK1SCN10ATRPV1MLKLLCK | |
| SCHEMBL15116803 | 0.84 | AAK1 (0.55) | AAK1SCN10ATRPV1MLKLLCK | |
| SCHEMBL16532762 | 0.83 | AAK1 (0.50) | AAK1LCK | |
| SCHEMBL15116827 | 0.81 | AAK1 (0.52) | AAK1SCN10ATRPV1MLKLLIPG | |
| SCHEMBL20054464 | 0.81 | AAK1 (0.52) | AAK1SCN10ATRPV1MLKLLIPG | |
| SCHEMBL15116746 | 0.81 | AAK1 (0.50) | AAK1SCN10ALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |